Please Wait.....
Report
South Korea Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032
Market Report I 2024-06-17 I 134 Pages I Inkwood Research
KEY FINDINGS
The South Korea RNA interference (RNAi) drug delivery market is predicted to develop at a CAGR of 21.61% over the forecast period of 2024-2032. It is set to reach a revenue of $6901.97 million by 2032.
MARKET INSIGHTS
The South Korea RNA interference (RNAi) drug delivery market is witnessing growth and interest due to several key factors. One of these factors is the application of RNAi drugs in cancer treatment, which has garnered considerable attention in the medical community. RNAi technology offers a promising approach to target specific genes involved in cancer progression, potentially leading to more effective and personalized treatment options for patients.
Another area driving the traction for RNAi drugs in South Korea is the management of infectious diseases. RNAi-based therapeutics show potential in addressing infectious diseases by targeting viral or bacterial genes, thereby inhibiting their replication and spread. This application has become increasingly relevant, especially in the context of emerging infectious disease threats and the need for innovative treatment strategies.
A notable trend in the South Korea RNA interference (RNAi) drug delivery market is the substantial increase in venture funding. This influx of investment reflects growing confidence in the potential of RNAi technologies and their commercial viability. Increased funding enables research and development efforts, clinical trials, and the commercialization of RNAi drugs, driving market expansion and innovation.
Despite the positive momentum, challenges exist that could impact market demand and growth. One such challenge is the complexity of RNAi technology, which may pose hurdles in terms of development, production, and regulatory approval processes. The intricate mechanisms involved in RNA interference require robust expertise and infrastructure, potentially affecting market uptake and adoption rates.
Regulatory challenges also play a significant role in shaping the market landscape in South Korea. Stringent regulatory frameworks and approval processes can contribute to delays and uncertainties in bringing RNAi-based therapeutics to market. Navigating these regulatory hurdles effectively will be crucial for market players to capitalize on the full potential of RNAi technologies in the country's healthcare sector.
SEGMENTATION ANALYSIS
The South Korea RNA interference (RNAi) drug delivery market segmentation incorporates the market by application and technology. The technology segment is further classified into nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery, and aptamer drug delivery. Within the technology segment, nanoparticle drug delivery stands out as a frontrunner. Nanoparticles offer a versatile platform for RNAi drug delivery, enabling targeted delivery to specific tissues or cells while minimizing off-target effects. This precision targeting enhances the therapeutic potential of RNAi drugs, making them more effective in treating complex diseases such as cancer, genetic disorders, and viral infections.
Pulmonary drug delivery represents another significant aspect of the market segmentation. With advancements in inhalation technology, RNAi drugs can be delivered directly to the lungs, offering targeted therapy for respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. This route of delivery improves drug efficacy and reduces systemic side effects, making it a preferred choice for respiratory therapeutics.
Nucleic acid drug delivery is a cornerstone of RNAi therapeutics, encompassing a wide range of delivery systems designed to transport RNA molecules into target cells. These delivery systems include lipid nanoparticles, viral vectors, and polymer-based carriers, each offering unique advantages in terms of stability, cellular uptake, and payload capacity. The continuous innovation in nucleic acid delivery technologies drives the growth and diversification of the RNAi drug delivery market in South Korea.
Aptamer drug delivery emerges as a promising area within the market segmentation, leveraging the specificity and binding affinity of aptamers to deliver RNAi payloads with precision. Aptamers, often referred to as 'chemical antibodies,' can be engineered to target specific molecules or cell surface receptors, enabling targeted delivery of RNAi drugs to diseased cells while sparing healthy tissues. This targeted approach reduces systemic toxicity and improves therapeutic outcomes, positioning aptamer-based drug delivery as a key player in the evolving field of RNAi therapeutics.
COMPETITIVE ANALYSIS
Top players operating in the South Korea RNA interference (RNAi) drug delivery market include Arbutus Biopharma Corp, Silence Therapeutics PLC, Sirnaomics Inc, etc.
Arbutus Biopharma, previously recognized as Tekmira, is a clinical-stage biopharmaceutical entity renowned for its profound virology proficiency. Its primary objective is to address ailments that lack adequate medical solutions. Situated in the United States, the company boasts formidable in-house research capabilities that have resulted in a remarkable collection of resources dedicated to combating various viral disorders.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
2.6.1. CARDIOLOGY IS THE FASTEST-GROWING RNAI DRUG DELIVERY APPLICATION
2.6.2. NANOPARTICLE DRUG DELIVERY IS THE MAJORLY PREFERRED RNAI DRUG DELIVERY TECHNOLOGY
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING DEMAND FOR RNA-BASED THERAPEUTICS TO STIMULATE MARKET GROWTH
3.1.2. RISING PREVALENCE OF CHRONIC DISEASES FOSTERS MARKET DEMAND
3.1.3. GROWING INVESTMENT IN RNA-BASED RESEARCH TO ESCALATE THE MARKET GROWTH
3.2. KEY RESTRAINTS
3.2.1. THE COMPLEXITY OF RNAI TECHNOLOGY IS PREDICTED TO HINDER MARKET DEMAND
3.2.2. REGULATORY CHALLENGES ARE EXPECTED TO FURTHER COMPLICATE MARKET GROWTH
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RNAI DRUGS HAVE APPLICATIONS IN CANCER TREATMENT
4.1.2. INFECTIOUS DISEASES ARE LEADING TO INCREASED TRACTION IN RNAI DRUGS
4.1.3. VENTURE FUNDING FOR RNAI DRUGS HAS INCREASED SUBSTANTIALLY
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR SOUTH KOREA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. PRIMARY ACTIVITIES
4.6.1.1. RESEARCH AND DEVELOPMENT (R&D)
4.6.1.2. MANUFACTURING
4.6.1.3. LOGISTICS AND DISTRIBUTION
4.6.1.4. MARKETING AND SALES
4.6.1.5. AFTER-SALES SERVICE
4.6.2. SUPPORT ACTIVITIES
4.6.2.1. PROCUREMENT
4.6.2.2. TECHNOLOGY DEVELOPMENT
4.6.2.3. HUMAN RESOURCE MANAGEMENT
4.6.2.4. FIRM INFRASTRUCTURE
4.6.2.5. REGULATORY AFFAIRS AND COMPLIANCE
4.7. KEY BUYING CRITERIA
4.7.1. EFFICACY AND SAFETY
4.7.2. MECHANISM OF ACTION AND TARGET SPECIFICITY
4.7.3. DELIVERY SYSTEM AND ADMINISTRATION ROUTE
4.7.4. COMPETITIVE ADVANTAGE AND DIFFERENTIATION
4.7.5. REGULATORY APPROVAL AND COMPLIANCE
4.7.6. COST AND REIMBURSEMENT
4.7.7. INTELLECTUAL PROPERTY AND EXCLUSIVITY
4.7.8. MANUFACTURING CAPABILITIES AND SUPPLY CHAIN
4.7.9. COMPANY REPUTATION AND EXPERIENCE
5. MARKET BY APPLICATION
5.1. ONCOLOGY
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. INFECTIOUS DISEASE
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. NEUROLOGY
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
5.4. CARDIOLOGY
5.4.1. MARKET FORECAST FIGURE
5.4.2. SEGMENT ANALYSIS
5.5. METABOLIC DISORDERS
5.5.1. MARKET FORECAST FIGURE
5.5.2. SEGMENT ANALYSIS
5.6. OPHTHALMOLOGY
5.6.1. MARKET FORECAST FIGURE
5.6.2. SEGMENT ANALYSIS
5.7. UROLOGY
5.7.1. MARKET FORECAST FIGURE
5.7.2. SEGMENT ANALYSIS
5.8. OTHER APPLICATIONS
5.8.1. MARKET FORECAST FIGURE
5.8.2. SEGMENT ANALYSIS
6. MARKET BY TECHNOLOGY
6.1. NANOPARTICLE DRUG DELIVERY
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. PULMONARY DRUG DELIVERY
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. NUCLEIC ACID DRUG DELIVERY
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
6.4. APTAMER DRUG DELIVERY
6.4.1. MARKET FORECAST FIGURE
6.4.2. SEGMENT ANALYSIS
7. COMPETITIVE LANDSCAPE
7.1. KEY MARKET STRATEGIES
7.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.2. PARTNERSHIPS & AGREEMENTS
7.2. COMPANY PROFILES
7.2.1. ALNYLAM PHARMACEUTICALS INC
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCT PORTFOLIO
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. ARBUTUS BIOPHARMA CORP
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCT PORTFOLIO
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. IONIS PHARMACEUTICALS INC
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCT PORTFOLIO
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. SIRNAOMICS INC
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCT PORTFOLIO
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. SILENCE THERAPEUTICS PLC
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCT PORTFOLIO
7.2.5.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - RNA INTERFERENCE (RNAI) DRUG DELIVERY
TABLE 2: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 7: LIST OF PARTNERSHIPS & AGREEMENTS
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR SOUTH KOREA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
FIGURE 9: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 10: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY INFECTIOUS DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 11: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NEUROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY CARDIOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 13: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY METABOLIC DISORDERS, 2024-2032 (IN $ MILLION)
FIGURE 14: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OPHTHALMOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 15: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 16: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2024-2032 (IN $ MILLION)
FIGURE 17: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2023
FIGURE 18: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NANOPARTICLE DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 19: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 20: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NUCLEIC ACID DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 21: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APTAMER DRUG DELIVERY, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security